Abbott Laboratories (ABT) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Abbott Laboratories (NYSE: ABT) in the last few weeks:

• 4/22/2026 – Abbott Laboratories was downgraded by Daiwa Securities Group Inc. from “outperform” to “neutral”. They now have a $92.00 price target on the stock.
• 4/21/2026 – Abbott Laboratories had its price target lowered by Argus from $140.00 to $125.00. They now have a “buy” rating on the stock.
• 4/21/2026 – Abbott Laboratories had its price target lowered by Leerink Partners from $119.00 to $106.00. They now have a “market perform” rating on the stock.
• 4/20/2026 – Abbott Laboratories had its price target lowered by UBS Group AG from $158.00 to $135.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Abbott Laboratories had its price target lowered by Barclays PLC from $144.00 to $143.00. They now have an “overweight” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Royal Bank Of Canada from $135.00 to $130.00. They now have an “outperform” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Sanford C. Bernstein from $125.00 to $110.00. They now have an “outperform” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Evercore Inc from $134.00 to $120.00. They now have an “outperform” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Raymond James Financial, Inc. from $130.00 to $115.00. They now have an “outperform” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Mizuho from $125.00 to $115.00. They now have a “neutral” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Wells Fargo & Company from $122.00 to $109.00. They now have an “overweight” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by JPMorgan Chase & Co. from $123.00 to $110.00. They now have an “overweight” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Piper Sandler from $135.00 to $115.00. They now have an “overweight” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Jefferies Financial Group Inc. from $145.00 to $135.00. They now have a “buy” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Citigroup Inc. from $136.00 to $108.00. They now have a “buy” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by TD Cowen from $137.00 to $115.00. They now have a “buy” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Oppenheimer Holdings, Inc. from $132.00 to $115.00. They now have an “outperform” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Benchmark Co. from $145.00 to $120.00. They now have a “buy” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its “buy” rating reaffirmed by BTIG Research. They now have a $131.00 price target on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Stifel Nicolaus from $145.00 to $120.00. They now have a “buy” rating on the stock.
• 4/17/2026 – Abbott Laboratories had its price target lowered by Bank of America Corporation from $150.00 to $120.00. They now have a “buy” rating on the stock.
• 4/8/2026 – Abbott Laboratories had its price target raised by Barclays PLC from $142.00 to $144.00. They now have an “overweight” rating on the stock.
• 4/8/2026 – Abbott Laboratories had its price target lowered by The Goldman Sachs Group, Inc. from $140.00 to $121.00. They now have a “buy” rating on the stock.
• 4/6/2026 – Abbott Laboratories had its price target lowered by Evercore Inc from $138.00 to $134.00. They now have an “outperform” rating on the stock.
• 3/31/2026 – Abbott Laboratories had its price target lowered by BTIG Research from $140.00 to $131.00. They now have a “buy” rating on the stock.
• 3/11/2026 – Abbott Laboratories had its price target lowered by Citigroup Inc. from $140.00 to $136.00. They now have a “buy” rating on the stock.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. Abbott Laboratories’s payout ratio is 70.59%.

Insider Activity at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares in the company, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,055 shares of company stock worth $353,097 in the last 90 days. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.